{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T12:58:23Z","timestamp":1790600303743,"version":"4.1.0"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012352","name":"Universit\u00e0 degli Studi di Milano","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012352","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Alemtuzumab treatment for multiple sclerosis frequently induces Graves\u2019 disease (GD), characterized by common coexistence of stimulating and blocking anti-thyrotropin receptor autoantibodies (TRAb), causing fluctuations of thyroid function. Alemtuzumab-induced TRAb-positive hypothyroidism is also common. These conditions are challenging to manage during pregnancy, considering the imperative necessity to maintain euthyroidism to minimize risks for both pregnancy and fetal\/neonatal outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We reviewed the clinical course and therapeutic management of four pregnant women affected with alemtuzumab-induced GD or TRAb-positive hypothyroidism followed at our Institution, and seven additional cases published in literature.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At our institution two patients with alemtuzumab-induced GD (one diagnosed before pregnancy, the other during the third trimester) showed a good control of thyroid function on anti-thyroid drugs (ATD). Two women had alemtuzumab-induced TRAb positive hypothyroidism; during pregnancy thyroid function was partially controlled with levothyroxine (LT4) alone in one case, and fully controlled with block and replace (ATD and LT4) in the other case. No pregnancy or fetal\/neonatal negative outcomes were observed, except for preterm delivery of a healthy baby in Case 3, due to emergency cesarean section for pre-eclampsia progressing to HELLP syndrome. The literature search showed seven additional cases of pregnant women with alemtuzumab-induced GD (N\u00a0=\u00a05) or TRAb-positive hypothyroidism (N\u00a0=\u00a02), mainly diagnosed during gestation, especially in the first trimester. Six newborns developed transient thyroid dysfunction, often requiring treatment and later resolved.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The clinical management of alemtuzumab-induced thyroid dysfunction during pregnancy is challenged by frequent difficult maternal biochemical thyroid control and TRAb-mediated fetal\/neonatal thyroid dysfunction. These patients need to be managed in a specialist setting, with close monitoring of maternal thyroid function and fetal\/neonatal parameters, especially in cases with high TRAb titers.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1955471","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T12:03:28Z","timestamp":1790597008000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Management of pregnancy in patients with Graves\u2019 disease secondary to alemtuzumab: a case series and literature review"],"prefix":"10.3389","volume":"17","author":[{"given":"Federico","family":"Crapella","sequence":"first","affiliation":[{"name":"Department of Clinical Sciences and Community Health, Department of Excellence 2023-2027, University of Milan","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Muller","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences and Community Health, Department of Excellence 2023-2027, University of Milan","place":["Milan, Italy"]},{"name":"Endocrinology Unit, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10875-009-9327-3","article-title":"B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis","volume":"30","author":"Thompson","year":"2010","journal-title":"J ClinImmunol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1136\/jnnp-2011-300826","article-title":"Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis","volume":"83","author":"Hill-Cawthorne","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B3","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s40263-016-0394-8","article-title":"Alemtuzumab use in clinical practice: Recommendations from European Multiple Sclerosis Experts","volume":"31","author":"Berger","year":"2017","journal-title":"CNS Drugs"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(12)61768-1","article-title":"Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial","volume":"380","author":"Coles","year":"2012","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-2201","article-title":"Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis","volume":"99","author":"Daniels","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1530\/etj-25-0007","article-title":"Clinical management of alemtuzumab-induced autoimmune thyroid diseases: a narrative review","volume":"14","author":"Manso","year":"2025","journal-title":"Eur Thyroid J"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1177\/20552173221142741","article-title":"Endocrine and multiple sclerosis outcomes in patients with autoimmune thyroid events in the alemtuzumab CARE-MS studies","volume":"9","author":"Dayan","year":"2023","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-00359","article-title":"Alemtuzumab-induced thyroid dysfunction exhibits distinctive clinical and immunological features","volume":"103","author":"Pariani","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-022-01832-4","article-title":"Graves' disease induced by Alemtuzumab in relapsing-remitting multiple sclerosis patients: an observational study in a reference center","volume":"45","author":"Rodriguez de Vera Gomez","year":"2022","journal-title":"J Endocrinol Invest"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad540","article-title":"Prevalence, risk factors, and clinical and biochemical characteristics of alemtuzumab-induced Graves disease","volume":"109","author":"Ueland","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1159\/000500881","article-title":"2019 European Thyroid Association Guidelines on the management of thyroid dysfunction following immune reconstitution therapy","volume":"8","author":"Muller","year":"2019","journal-title":"Eur Thyroid J"},{"key":"B12","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1177\/10507256261445624","article-title":"American Thyroid Association 2026 Guidelines for thyroid disease in preconception, pregnancy, and postpartum","volume":"36","author":"Korevaar","year":"2026","journal-title":"Thyroid"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvab044","article-title":"Management of severe Graves' hyperthyroidism in pregnancy following immune reconstitution therapy in multiple sclerosis","volume":"5","author":"Hammerstad","year":"2021","journal-title":"J Endocr Soc"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2017.0413","article-title":"Maternal thyrotropin receptor antibody concentration and the risk of fetal and neonatal thyrotoxicosis: a systematic review","volume":"28","author":"van Dijk","year":"2018","journal-title":"Thyroid"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1530\/eje-20-1320","article-title":"Prevalence and course of thyroid dysfunction in neonates at high risk of Graves' disease or with non-autoimmune hyperthyroidism","volume":"184","author":"Benlarbi","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2018.0232","article-title":"Longitudinal characterization of autoantibodies to the thyrotropin receptor (TRAb) during alemtuzumab therapy: Evidence that TRAb may precede thyroid dysfunction by many years","volume":"28","author":"Muller","year":"2018","journal-title":"Thyroid"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2020.05.049","article-title":"Treatment of multiple sclerosis: a review","volume":"133","author":"Hauser","year":"2020","journal-title":"Am J Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2019.0150","article-title":"Prevention of orbitopathy by oral or intravenous steroid prophylaxis in short duration Graves' disease patients undergoing radioiodine ablation: a prospective randomized control trial study","volume":"29","author":"Vannucchi","year":"2019","journal-title":"Thyroid"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1530\/eje-21-0479","article-title":"The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy","volume":"185","author":"Bartalena","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.73.8.639","article-title":"Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach","volume":"73","author":"Mourits","year":"1989","journal-title":"Br J Ophthalmol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1046\/j.1365-2265.1997.2331047.x","article-title":"Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy","volume":"47","author":"Mourits","year":"1997","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-022-00981-3","article-title":"Thyroid autoimmunity following alemtuzumab treatment in multiple sclerosis patients: a prospective study","volume":"23","author":"Kazakou","year":"2023","journal-title":"Clin Exp Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"A919","DOI":"10.1210\/jendso\/bvab048.1877","article-title":"Alemtuzumab-induced hypothyroidism presenting in pregnancy - the first 2 reported cases","volume":"5","author":"Scott","year":"2021","journal-title":"J Endocr Soc"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-02435","article-title":"Letter to the editor: \"Alemtuzumab-induced thyroid dysfunction exhibits distinctive clinical and immunological features","volume":"104","author":"Garrahy","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-02593","article-title":"Response to letter to the editor: \"Alemtuzumab-induced thyroid dysfunction exhibits distinctive clinical and immunological features","volume":"104","author":"Thakar","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1722459","article-title":"Management of alemtuzumab-induced Graves' disease in pregnancy: a case report and literature review","volume":"16","author":"Teliti","year":"2025","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12980","article-title":"Prevalence and clinical relevance of thyroid stimulating hormone receptor-blocking antibodies in autoimmune thyroid disease","volume":"189","author":"Diana","year":"2017","journal-title":"Clin Exp Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa129","article-title":"CATS II long-term anthropometric and metabolic effects of maternal sub-optimal thyroid function in offspring and mothers","volume":"105","author":"Muller","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2020.101436","article-title":"Indications for treatment of subclinical hypothyroidism and isolated hypothyroxinaemia in pregnancy","volume":"34","author":"Taylor","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14010190","article-title":"Autoimmune thyroid disease and pregnancy: The interaction between genetics, epigenetics and environmental factors","volume":"14","author":"Bogovic Crncic","year":"2024","journal-title":"J Clin Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(13)70086-x","article-title":"Hyperthyroidism in pregnancy","volume":"1","author":"Cooper","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-3588","article-title":"Hyperthyroidism incidence fluctuates widely in and around pregnancy and is at variance with some other autoimmune diseases: a Danish population-based study","volume":"100","author":"Andersen","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1186\/s40842-018-0054-7","article-title":"Graves' hyperthyroidism in pregnancy: a clinical review","volume":"4","author":"Nguyen","year":"2018","journal-title":"Clin Diabetes Endocrinol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.64","article-title":"The unique immunological and microbial aspects of pregnancy","volume":"17","author":"Mor","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2019-01343","article-title":"Maternal thyroid function, use of antithyroid drugs in early pregnancy, and birth defects","volume":"104","author":"Andersen","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-2831","article-title":"Birth defects after early pregnancy use of antithyroid drugs: a Danish nationwide study","volume":"98","author":"Andersen","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1530\/ey.15.3.9","article-title":"Antithyroid drugs and congenital malformations: a nationwide Korean cohort study","volume":"168","author":"Seo","year":"2018","journal-title":"Ann Intern Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2009.0169","article-title":"The role of propylthiouracil in the management of Graves' disease in adults: report of a meeting jointly sponsored by the American Thyroid Association and the Food and Drug Administration","volume":"19","author":"Bahn","year":"2009","journal-title":"Thyroid"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1055\/s-0039-1694035","article-title":"Role of maternal thyroid-stimulating immunoglobulin in Graves' disease for predicting perinatal thyroid dysfunction","volume":"9","author":"Cui","year":"2019","journal-title":"AJP Rep"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1955471\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T12:03:29Z","timestamp":1790597009000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1955471\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":39,"alternative-id":["10.3389\/fendo.2026.1955471"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1955471","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"article-number":"1955471"}}